What question did this study set out to answer?

Assess the effectiveness of UGN-102 in achieving durable complete responses in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

March 28, 2026Open Access

UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial

Key Points

Assess the effectiveness of UGN-102 in achieving durable complete responses in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
Conducted a Phase 3 trial with a single-arm design.
Patients received UGN-102 treatment.
Measured event-free survival over a 24-month period.
Patients showed a high probability of remaining event-free at 24 months following treatment.
UGN-102 resulted in durable complete responses for recurrent low-grade intermediate-risk cases.

Abstract

Patients who achieved CR following UGN-102 treatment had a high probability of remaining event-free 24 months later. These data indicate UGN-102 is a novel, nonsurgical treatment that provides a durable CR for patients with recurrent LG-IR-NMIBC. Study limitations included the single-arm design and the limited racial diversity of the patients.

UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial

Key Points

Abstract

Cite This Study